ClinicalTrials.gg
CompletedNCT01363752ADHEREUpdated Oct 31, 2024

A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.

A Phase 4 interventional study of Advagraf and Mycophenolate Mofetil in Kidney Transplantation, sponsored by Astellas Pharma Inc. Completed at 58 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Astellas Pharma Inc · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
853
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 109 studies in Acute Kidney Injury with a site in Germany — 21 open to participants now, 24 under way, 1 of them phase 3. Acute Kidney Injury · Germany.

Enrollment
5th of 62
853 · median 112
Started
2011
with 2 others
Phase 4
4 of 109
1 open now
Registered
12th of 109
by date

Among the 109 studies in Acute Kidney Injury with a site in Germany, this one is the 5th largest by enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2011, is one of 4 in phase 4, and was the 12th registered.

Acute Kidney Injury

1,691 studies on the registry are indexed under Acute Kidney Injury; 393 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

21 of the 109 studies in Acute Kidney Injury with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Acute Kidney Injury with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effect of two anti-rejection therapy regimens on kidney function in kidney transplant recipients.

Read the detailed description

This study will evaluate the potential to reduce nephrotoxic calcineurin inhibitors (CNI) therapy by lowering tacrolimus exposure from Advagraf® in combination with the non-nephrotoxic immunosuppressant sirolimus to avoid the risk of acute graft rejection, compared with an Advagraf® and Mycophenolate Mofetil (MMF) immunosuppressive regimen.

03

Conditions studied

  • Kidney Transplantation

Browse trials for

Keywords

  • Kidney
  • Kidney Failure, Acute
  • Astagraf XL
  • Immunosuppression
  • Advagraf
  • Tacrolimus
  • Transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • End stage kidney disease and a suitable candidate for primary renal transplantation or re-transplantation (unless the graft was lost from rejection within 6 months)
  • Receiving a kidney transplant from a deceased or living (non Human Leukocyte Antigen [HLA] identical) donor with compatible ABO blood type
  • Female subject of has a negative serum or urine pregnancy test at enrollment
  • Female and male subjects agree to maintain highly effective during the study and for 90 days after discontinuation of dosing with study drugs. A highly effective method of birth control is defined as those which result in a low failure rate (CPMP/ ICH/ 286/ 95 modified) of less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some Intrauterine Devises (IUDs), sexual abstinence or vasectomized partner

Exclusion criteria

Exclusion Criteria:

  • Receiving or having previously received an organ transplant other than a kidney
  • Cold ischemia time of the donor kidney > 30 hours
  • Panel Reactive Antibody (PRA) >20%
  • Receiving a graft from a non-heart-beating donor other than of Maastricht category 3 (withdrawal of support awaiting cardiac arrest)
  • Significant liver disease, defined as having continuously elevated / ALT and/ or SGOT/ AST and/ or total levels ≥ 2 times the upper value of the normal range of the site or is receiving a graft from a or B positive donor
  • Requiring initial sequential or parallel therapy with antibody preparation(s)
  • Requiring ongoing dosing with a systemic immunosuppressive drug prior to transplantation (other than minimal levels of immunosuppression following failure of previous transplantation without nephrectomy)
  • Significant, uncontrolled concomitant infections and/ or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer
  • Pregnant woman or breast-feeding mother
  • Subject or donor known to be positive
  • Known allergy or intolerance to tacrolimus, macrolide antibiotics, , sirolimus, MMF or any of the product or iodine
  • Evidence of malignant disease within the last 5 years, not including non-malignant skin cancers
  • Currently participating in another clinical trial, and/ or has taken an investigational drug within 28 days prior to enrollment
  • Unlikely to comply with the visits scheduled in the protocol
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
853 participants (actual)

Study arms

  • Active comparator
    Advagraf + MMF + Steroids

    Without sirolimus

    Drug: Advagraf · Drug: Mycophenolate Mofetil · Drug: Corticosteroids

  • Experimental
    Advagraf + MMF + Steroids + Sirolimus

    With sirolimus; MMF withdrawn on Day 28; Sirolimus introduced on Day 28

    Drug: Advagraf · Drug: Mycophenolate Mofetil · Drug: Sirolimus · Drug: Corticosteroids

Interventions

  • oral

    Also known as: FK506E, Prolonged release tacrolimus

  • oral

    Also known as: CellCept

  • oral

    Also known as: Rapamune

  • DrugCorticosteroids

    i.v. and oral

06

What researchers measure

Primary outcomes

  1. Glomerular Filtration Rate (GFR) estimated by iohexol clearance at Week 52 post kidney transplantation

    Time frame: up to 1 year

Secondary outcomes

  1. Efficacy failure

    Composite endpoint defined as graft loss (re-transplantation, nephrectomy, death or dialysis ongoing at the study end) or subject withdrawal

    Time frame: up to 1 year

  2. GFR at Week 52 post kidney transplantation by Modification Diet in Renal Disease (MDRD) formula

    Time frame: up to 1 year

  3. GFR at Week 52 post kidney transplantation by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula

    Time frame: up to 1 year

  4. Calculated creatinine clearance at Week 52 post kidney transplantation by Cockcroft and Gault formula

    Time frame: up to 1 year

  5. Incidence of clinical acute rejection

    Time frame: up to 1 year

  6. Time to clinical acute rejection

    Time frame: up to 1 year

  7. Incidence of Biopsy Confirmed Acute Rejection

    Time frame: up to 1 year

  8. Time to Biopsy Confirmed Acute Rejection

    Time frame: up to 1 year

  9. Subject survival

    Time frame: up to 1 year

  10. Graft survival

    Time frame: up to 1 year

  11. New Onset Diabetes Mellitus (NODM) as per American Diabetic Association (ADA) criteria

    Time frame: up to 1 year

07

Study locations

58 sites
  • 5042
    New Lambton, NSW 2305, Australia
  • 5043
    Perth, WA 6009, Australia
  • 1141
    Innsbruck, 6020, Austria
  • 1142
    Linz, 4020, Austria
  • 1140
    Vienna, 1090, Austria
  • 3240
    Minsk, 220116, Belarus
  • 1241
    Leuven, 3000, Belgium
  • 1240
    Liege 1, 4000, Belgium
  • Site 1441
    Brno, 656 91, Czechia
  • 1440
    Ostrava - Poruba, 78 52, Czechia
  • 1752
    Amiens Cedex, 80054, France
  • 1740
    Brest Cedex 2, 29609, France
  • 1742
    Clermont-Ferrand Cedex 1, 63003, France
  • 1746
    Creteil Cedex, 94010, France
  • 1750
    Dijon, 21000, France
  • 1741
    Le Kremilin Bicetre Cedex, 94275, France
  • 1749
    Paris Cedex 15, 75743, France
  • 1751
    Toulouse Cedex 9, 31059, France
  • 1748
    Tours cedex 9, 37044, France
  • 1745
    Vandoeuvre Les Nancy Cedex, 54511, France
  • 1541
    Bochum, 44892, Germany
  • 1542
    Erlangen, 91054, Germany
  • 1543
    Essen, 45147, Germany
  • 1544
    Frankfurt, 60596, Germany
  • 1545
    Hann.Munden, 34346, Germany
  • 1540
    Hannover, 30625, Germany
  • 1546
    Heidelberg, 69120, Germany
  • 1547
    Kiel, 24105, Germany
  • 1548
    Leipzig, 04103, Germany
  • 1549
    Munchen, 81377, Germany
  • 1550
    Munster, 48149, Germany
  • 5441
    Hong Kong, Hong Kong
  • 1940
    Budapest, 1082, Hungary
  • 2144
    Palermo, 90124, Italy
  • 2143
    Roma, 00168, Italy
  • 2140
    Siena, 53100, Italy
  • 5245
    Busan, 614-735, Korea, Republic of
  • 5243
    Daegu, 700-721, Korea, Republic of
  • 5242
    Seoul, 110-744, Korea, Republic of
  • 5241
    Seoul, 120-752, Korea, Republic of
  • 5244
    Seoul, 138-736, Korea, Republic of
  • 2440
    Maastricht, 6229 HX, Netherlands
  • 2643
    Katowice, 40-027, Poland
  • 2640
    Lodz, 91-153, Poland
  • 2641
    Poznan, 60-479, Poland
  • 2841
    Kemerovo, 650066, Russian Federation
  • 2843
    Moscow, 115446, Russian Federation
  • 2842
    Omsk, 644112, Russian Federation
  • 2840
    Vol'ginskiy, 404120, Russian Federation
  • 1640
    Alicante, 03010, Spain
  • 1641
    Barcelona, 08907, Spain
  • 1643
    Santander, 39008, Spain
  • 1642
    Vizcaya, 48903, Spain
  • 5343
    Tainan, 70403, Taiwan
  • 5342
    Taoyuan, 33305, Taiwan
  • 3042
    Istanbul, 07058, Turkey
  • 3043
    Istanbul, 34245, Turkey
  • 3044
    Istanbul, 34732, Turkey
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Sep 2013, 30 months.

Of 46 phase 4 interventional studies under Acute Kidney Injury, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2011
First posted
Jun 2, 2011
StartActual
Mar 8, 2011
Primary completionActual
Sep 18, 2013
CompletionActual
Sep 18, 2013
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01363752
Responsible party
Sponsor
First posted
Jun 2, 2011
Start date
Mar 8, 2011
Primary completion
Sep 18, 2013
Completion
Sep 18, 2013
Last update
Oct 31, 2024

Study contacts

Use Central Contact
study director · Astellas Pharma Europe Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion